Levopront (Levodropropizine)

Levodropropizine, the active ingredient in Levopront, is an antitussive presented as an oral formulation for oral use. It suppresses the cough reflex in patients with dry, non‑productive cough, providing symptomatic relief in both adults and children, and is available in dosage forms suitable for pediatric and adult patients.

GNH USA supplies Levopront as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with rigorous quality assurance and regulatory compliance that ensures product integrity across global markets through a reliable supply chain.

Levodropropizine is an antitussive that acts on the peripheral cough reflex pathway to relieve cough symptoms.

- Dry cough: Reduces frequency and intensity of non‑productive cough, providing symptomatic relief. - Irritative cough: Alleviates cough triggered by throat irritation, helping improve comfort. - Cough associated with mild respiratory infections: Helps control cough without central nervous system effects.

Levodropropizine is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nausea: Mild stomach upset may be reported. - Dizziness: Transient light‑headedness in some patients. - Headache: Occasional mild headache. - Dry mouth: Reduced salivation leading to a dry sensation. - Taste alteration: Slight change in taste perception. - Somnolence: Mild drowsiness, especially at higher doses.

Serious or Rare Side Effects: - Allergic reaction: Rash, itching, or urticaria indicating hypersensitivity. - Angioedema: Swelling of face, lips, or tongue requiring immediate medical attention. - Hepatic dysfunction: Elevated liver enzymes in rare cases. - Neutropenia: Decreased white blood cell count, increasing infection risk. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Anaphylaxis: Rapid onset of systemic allergic response, potentially life‑threatening.

When prescribing or dispensing Levopront, consider the following precautions.

- Assess patient history: Review for hypersensitivity to levodropropizine or other antitussives. - Monitor hepatic function: Use cautiously in patients with liver disease. - Use with caution in children: Follow pediatric dosing guidelines and monitor response. - Avoid concomitant use with other central cough suppressants unless advised by a clinician. - Pregnancy and lactation: Evaluate risk–benefit before prescribing. - Store at ambient temperature below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Levodropropizine has a limited interaction profile, but certain combinations require attention.

Major Interactions (Avoid): - Combined use with other opioid‑containing antitussives: May increase risk of respiratory depression. - Strong CYP3A4 inhibitors (if metabolized by this pathway): Potentially raise plasma levels of levodropropizine. - MAO inhibitors: Caution due to theoretical risk of serotonin‑related effects.

Moderate Interactions (Monitor Closely): - Alcohol: May enhance sedative effects and dizziness. - Antihistamines: May increase antitussive effect, requiring dose adjustment. - Bronchodilators: Monitor for additive effects on cough control. - Herbal supplements (e.g., St. John’s wort): May alter metabolism, warranting observation.